Media

BONESUPPORT™ Announces Nature Publication Of Pre-Clinical Study Highlighting CERAMENT™’s Attractive Bone Remodeling Properties and as a Local Drug Delivery Platform for Bone Disease

Strongbridge Biopharma plc Announces Presentation of COR-003 and COR-005 Data at the European Congress of Endocrinology

NORDIC NANOVECTOR CAPITAL MARKETS DAY 2016 TO HIGHLIGHT STRONG PROGRESS TOWARDS VISION OF BECOMING A SIGNIFICANT PLAYER IN HAEMATOLOGICAL CANCERS

Wilson Therapeutics presents encouraging clinical data on Decuprate® at the Congress of the European Academy of Neurology

GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext’s regulated market in Paris

NORDIC NANOVECTOR TO HOST CAPITAL MARKETS DAY IN OSLO ON 31 MAY 2016

NORDIC NANOVECTOR ASA: NEW BOARD MEMBERS ELECTED BRINGING FURTHER EXPERTISE IN THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE CANCER THERAPIES

NORDIC NANOVECTOR ASA FIRST QUARTER 2016 RESULTS: STRONG PROGRESS ON ALL PRIORITIES AND EXECUTION ON TRACK

Wilson Therapeutics AB (PUBL) Interim Report January 1 – March 31, 2016